Rieckmann Traci R, Kovas Anne E, Cassidy Elaine F, McCarty Dennis
Department of Public Health & Preventive Medicine, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, United States.
Eval Program Plann. 2011 Nov;34(4):366-74. doi: 10.1016/j.evalprogplan.2011.02.003. Epub 2011 Mar 2.
State public health authorities are critical to the successful implementation of science based addiction treatment practices by community-based providers. The literature to date, however, lacks examples of state level policy strategies that promote evidence-based practices (EBPs). This mixed-methods study documents changes in two critical state-to-provider strategies aimed at accelerating use of evidence-based practices: purchasing levers (financial incentives and mechanisms) and policy or regulatory levers. A sample of 51 state representatives was interviewed. Single State Authorities for substance abuse treatment (SSAs) that fund providers directly or through managed care were significantly more likely to have contracts that required or encouraged evidence-based interventions, as compared to SSAs that fund providers indirectly through sub-state entities. Policy levers included EBP-related legislation, language in rules and regulations, and evidence-based criteria in state plans and standards. These differences in state policy are likely to result in significant state level variations regarding both the extent to which EBPs are implemented by community-based treatment providers and the quality of implementation.
州公共卫生当局对于社区服务提供者成功实施基于科学的成瘾治疗实践至关重要。然而,迄今为止的文献缺乏促进循证实践(EBPs)的州级政策策略实例。这项混合方法研究记录了旨在加速循证实践应用的两种关键的州对提供者策略的变化:采购杠杆(经济激励措施和机制)以及政策或监管杠杆。对51名州代表进行了访谈。与通过州以下实体间接资助提供者的单一州药物滥用治疗管理局(SSAs)相比,直接或通过管理式医疗资助提供者的SSAs更有可能签订要求或鼓励循证干预措施的合同。政策杠杆包括与循证实践相关的立法、规章制度中的措辞以及州计划和标准中的循证标准。州政策的这些差异可能会导致州一级在社区治疗提供者实施循证实践的程度以及实施质量方面出现显著差异。